Povrchové markery leukemických kmenových buněk u chronické myeloidní leukemie
| Title in English | Leukemic stem cell surface markers in chronic myeloid leukaemia |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Transfuze a hematologie dnes |
| MU Faculty or unit | |
| Citation | |
| Web | https://redakce.carecomm.cz/tahd/article/view/1334 |
| Doi | http://dx.doi.org/10.48095/cctahd2023prolekare.cz2 |
| Keywords | chronic myeloid leukaemia; leukemic stem cells; leukemic stem cell markers |
| Attached files | |
| Description | Treatment with tyrosine kinase inhibitors has revolutionized the management of CML, but only ~ 40% of patients achieve treatment-free remission. One of the underlying causes is persistent leukemic stem cells (LSCs) which are resistant to therapy and survive in quiescent form in the bone marrow niche. This LSC pool can serve as a source of CML reoccurrence and mutation acquisition, which can lead to treatment resistance and disease relapse. Thus, the ideal therapy goal is complete disease eradication including the LSCs. However, specific therapeutic targets are lacking, and even monitoring of these rare cells is problematic. Therefore, there has been intense research to find specific LSC markers which would allow distinction of LSCs from normal stem cells, description of LSC bio logy, and identification of potential therapeutic targets. This article reviews recent studies and clinical trials involving the problems of surface LSC markers in CML. |
| Related projects: |
|